Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Gemcitabine plus oxaliplatin vs best supportive care

All‐cause mortality at 1 year · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with best supportive care (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 0.78 [0.53, 1.15]
1 study · 40 participants
Very low

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus folinic acid

All‐cause mortality at 1 year · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with 5‐fluorouracil plus folinic acid (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 0.81 [0.55, 1.2]
1 study · 41 participants
Very low

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy

All‐cause mortality at 1 year · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 0.56 [0.21, 1.52]
1 study · 34 participants
Very low